Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
Trial details
- Registry ID
- NCT04057898
- Drugs studied
- MN-166
TrialRedline tracks 4 clinical trials sponsored by MediciNova: 1 Phase 2 / 3, 3 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALSNCT04057898 | MN-166 | Active not recruiting | 2027-04Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and HypertriglyceridemiaNCT05464784 | MN-001 | Active not recruiting | 2026-12-31Estimated |
| Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDSNCT04429555 | Ibudilast | Completed | 2022-06-30Actual |
| Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary FibrosisNCT02503657 | MN-001 | Completed | 2020-12-07Actual |
Names as written in the registry records.
Before: Dec 2025. After: Apr 2027.
NCT05464784 · MediciNova
Before: 31 Dec 2025. After: 31 Dec 2026.
Before: Recruiting. After: Active not recruiting.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change from baseline of FVC (forced vital capacity) at 26 weeks. After: Measure: Absolute Change From Baseline in Forced Vital Capacity for 26 Weeks Measure: Percent Change in Forced Vital Capacity From Baseline to Week 26 Measure: Absolute Change From Baseline in Forced Vital Capacity (% Predicted) Measure: Relative Change From Baseline in Percent Predicted Forced Vital Capacity From Baseline to Week 26 Measure: Semiannual Rate of Decline of Disease Activity Based on Forced Vital Capacity.